News | October 09, 2014

CardiacAssist Announces the First Human Use of Protek Duo Veno-Venous ECLS Kit

Texas man is the world’s first to receive the Protek Duofor treatment following surgery

October 9, 2014 — CardiacAssist Inc. announced that the first Protek Duo veno-venous extracorporeal life support (VV ECLS) kit was utilized Sept. 24, at Memorial Hermann Hospital in Houston. According to statements from the world-renowned heart failure team led by Biswajit Kar, Pranav Loyalka and Igor Gregoric, the Protek Duo ECLS kit was utilized when one patient’s heart function continued to deteriorate despite the successful implantation of a long-term left ventricular assist device (LVAD).

The Protek Duo cannula was placed during a short, minimally-invasive percutaneous procedure in the cardiac catheterization lab before returning the patient to the hospital’s cardiac intensive care unit, where many of the pharmaceuticals upon which the patient was dependent were able to be weaned. In combination with the TandemHeart pump, the Protek Duowas reported to deliver 4 liters per minute of blood flow, allowing the patient’s native heart to rest while augmenting flow to the implantable LVAD. The patient is now in the process of being weaned from the device and the outlook is favorable despite a long road to full recovery.

“Our team prides itself on our ability to offer patients the most advanced treatment options and technologies. On behalf of the entire team, I’d like to say that we are very proud to be the first center to use the Protek Duoas this technology provides a new opportunity to support a group of patients that previously had few alternatives,” said Kar, chief of the Medical Division Center for Advanced Heart Failure and professor of internal medicine at Memorial Hermann Hospital. “The Protek Duoperformed well and we plan on making it a permanent part of our treatment arsenal.”

The Protek Duoveno-venous cannula recently received U.S. Food and Drug Administration (FDA) 510(k) clearance as a single cannula for both venous drainage and reinfusion of blood via an internal jugular vein during ECLS procedures. Upon clearance, CardiacAssist initiated a limited commercial release in September and expects to begin full commercial release before the end of the year. “I would like to congratulate our team for bringing this revolutionary product through development and into commercial launch in record time,” said John Marous, president and CEO of CardiacAssist. “We are extremely happy with Protek Duo’s performance in the first of many opportunities to help patients in need.”

Related Content

BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies| September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
CardiAMP Heart Failure Trial Design Presented at Texas Heart Institute Symposium
News | Heart Failure| September 25, 2017
BioCardia Inc. announced the trial design for its pivotal Phase III CardiAMP Heart Failure Trial was presented during...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
Heart Failure Patients, Clinicians Have Differing Perceptions of Risk Level
News | Heart Failure| September 06, 2017
September 6, 2017 — Physicians identified a majority of patients with advanced...
Israeli Hospital Completes First Implant of CORolla Heart Failure Device
News | Heart Failure| September 05, 2017
Rambam Hospital in Haifa, Israel, recently became the first to use the CORolla device from Israeli start-up company...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD)| August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Sponsored Content | Videos | Cardiovascular Ultrasound| August 28, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
Overlay Init